In support of this idea, a recent report showed that higher levels of CREB3L1 expression strongly inversely correlated with tumor volume upon doxorubicin treatment in renal cell carcinoma xenografts (r = −0.891; p = 0.017) [22], leading to the suggestion that CREB3L1 could be a biomarker that predicts doxorubicin treatment outcome. The gene discussed is CREB3L1; the disease is neoplasm.